Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GENOVA, Inc. (9341.T)
Tokyo, JP
Operating within Japan, GENOVA, Inc. focuses on the digital healthcare market, providing both medical platform services and smart clinic solutions. Its offerings include Medical Doc, a comprehensive online platform that distributes diverse content, such as articles for healthcare institutions, patient experience narratives, treatment demonstrations, and general medical information. The company also developed Smart Clinic, an innovative telemedicine and consultation service that enables users to receive medical care from their homes or workplaces, bypassing the need for in-person hospital visits. Additionally, GENOVA offers a suite of clinic automation tools, including NOMOCa-Stand, a user-friendly automatic machine for reception and payments; NOMOCa-Regi, a dedicated self-pay terminal for clinic environments; and CLINIC BOT, an AI-driven chatbot system. GENOVA, Inc. was established in 2005 and is based in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.37% | +3.04% | +1.95% | -1.20% | +1.77% | -2.04% | -43.25% | -61.60% | -66.84% | -66.84% | -66.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+15.6% ★ Q1'26: +51.8% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%-80.1% Q1'26: -30.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+1.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+3.5% Q1'26: +11.7% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+10.4% ★ Q1'26: +43.9% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%-2.2% ★ Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×1.35× ★ Q1'26: 0.39× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
6.51B
est: 6.43B (+1.3%)
|
8.68B
est: 8.55B (+1.6%)
|
10.01B
est: 10.70B (-6.5%)
|
13.00B
13.00B – 13.00B
+21.5% YoY
|
15.40B
15.40B – 15.40B
+18.5% YoY
|
| EBITDA |
1.79B
est: 1.55B (+15.2%)
|
2.38B
est: 1.95B (+21.8%)
|
2.11B
est: 2.44B (-13.7%)
|
2.97B
2.97B – 2.97B
+21.5% YoY
|
3.51B
3.51B – 3.51B
+18.5% YoY
|
| EBIT |
1.73B
est: 1.51B (+15.2%)
|
2.30B
est: 1.84B (+24.8%)
|
2.03B
est: 2.31B (-12.2%)
|
2.81B
2.81B – 2.81B
+21.5% YoY
|
3.32B
3.32B – 3.32B
+18.5% YoY
|
| Net Income |
1.26B
est: 1.11B (+13.5%)
|
1.73B
est: 1.54B (+12.3%)
|
1.41B
est: 1.91B (-26.0%)
|
2.31B
2.31B – 2.31B
+21.1% YoY
|
2.82B
2.82B – 2.82B
+21.8% YoY
|
| SGA |
3.03B
est: 3.17B (-4.7%)
|
4.20B
est: 4.18B (+0.6%)
|
5.20B
est: 5.23B (-0.5%)
|
6.35B
6.35B – 6.35B
+21.5% YoY
|
7.53B
7.53B – 7.53B
+18.5% YoY
|
| EPS |
71.61
est: 62.10 (+15.3%)
|
97.36
est: 86.00 (+13.2%)
|
79.79
est: 106.80 (-25.3%)
|
129.30
129.30 – 129.30
+21.1% YoY
|
157.50
157.50 – 157.50
+21.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Core TOPIX ETF 1475.T | 0.00% | 62.0K | 0.05% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 768.77 | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akihisa Ueda | Executive Officer, GM of Finance Department & Director | — | male |
| Akira Shintani | Executive Officer & GM of Corporate Planning Office | — | — |
| Chifuyu Harada | Executive Officer & GM of HR Department | — | — |
| Eru Kamedano | Executive Officer & GM of President's Office | — | — |
| Koji Takeda | Executive Officer & Director | — | male |
| Noboru Oi | Executive Officer | — | — |
| Sho Inoue | Executive Officer, Head of Business Promotion Officer & Director | — | male |
| Takeshi Nakatani | Executive Officer & Fukuoka Branch Manager | — | — |
| Tomoki Hirase | President, Chief Executive Officer & Representative Director | — | male |
| Tomoyoshi Mano | Operating Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9341.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
